Pith. sign in

REVIEW 5 major objections 5 minor 8 references

Gefitinib-Induced Interface Engineering Enhances the Defect Formation Energy for Highly Efficient and Stable Perovskite Solar Cells

T0 review · 5 major / 5 minor · reviewed 2026-08-07 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗

Pith's one-line read Gefitinib modification of PEDOT:PSS strips away insulating PSS chains, passivates perovskite defects, and lifts cell efficiency from 17.01% to 19.63% while sharply improving humid-air stability.

desk verdict A plausible interface-engineering demonstration with real efficiency gains, but the mechanistic story is under-supported and the title overclaims what was actually measured. read the letter →

arxiv 2506.03611 v1 pith:ZWCSJP4Y submitted 2025-06-04 cond-mat.mtrl-sci physics.app-ph

Xianhu Wu , Guanglei Cui , Jieyu Bi , Gaojie Xia , Zewen Zuo , Min Gu This is my paper
classification cond-mat.mtrl-sciphysics.app-ph
keywords perovskitesolarcellsPEDOT:PSSgefitinibinterfaceengineeringdefectpassivationPSSremovaldevicestabilityholetransportlayer
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

This paper proposes that the drug molecule gefitinib can act as a dual-purpose interface modifier for perovskite solar cells built on PEDOT:PSS. The authors argue that gefitinib removes free, insulating PSS chains from the PEDOT:PSS surface, lowering the PSS-to-PEDOT ratio from 5.29 to 4.56, raising the hole-transport layer's conductivity, and shifting its valence-band edge closer to that of the perovskite. They also claim that the molecule's Cl, F, and NH groups passivate uncoordinated perovskite defects at the interface, reducing trap density and non-radiative recombination. On this basis, the open-circuit voltage rises from 1.077 to 1.110 V and the power conversion efficiency from 17.01% to 19.63%, with unencapsulated devices retaining 52.31% of initial efficiency after about 900 hours in humid air versus 11.42% for the control. The same gefitinib treatment at the SnO2/perovskite interface improves a conventional n-i-p cell from 22.46% to 23.89%.

What carries the argument

The central object is gefitinib, an organic molecule carrying Cl, F, and NH groups, applied as a thin modifier layer on PEDOT:PSS. It is claimed to act by displacing surface PSS chains (lowering the PSS/PEDOT ratio from 5.29 to 4.56), deepening the work function of PEDOT:PSS from -4.88 to -5.08 eV and its valence-band maximum from -5.09 to -5.26 eV, and passivating uncoordinated Pb sites through its electron-rich groups. The trap-filled-limit SCLC measurement with $N_t = 2\varepsilon_0\varepsilon V_{TFL}/(eL^2)$ is used to translate the observed $V_{TFL}$ drop into a reduced defect density.

What would settle it

Replace gefitinib with structural analogues that lack Cl, F, or NH groups one at a time: if the Pb 4f shift, Voc gain, and stability retention persist when the passivating groups are removed, the proposed chemical mechanism is wrong, whereas if they disappear only when all three groups are removed, the mechanism is confirmed. Alternatively, repeat the SCLC measurement over many devices with varied perovskite thickness; if the $V_{TFL}$ difference between Control and 3-Gftn falls within run-to-run scatter, the claimed defect-density reduction is not established.

Watch

Extended reading notes

Core claim

The central claim is that a single molecular layer of gefitinib at the PEDOT:PSS/perovskite buried interface does two things at once: it strips away non-conductive PSS chains from the PEDOT:PSS surface (XPS S ratio drops from 5.29 to 4.56, the PSS absorption peak shrinks, and conductivity rises) and chemically passivates perovskite defects through its Cl, F, and NH groups (Pb 4f peaks shift 0.20 eV, the trap-filled-limit voltage drops from 0.787 to 0.701 V, and the calculated defect density falls from $1.33 \times 10^{16}$ to $1.18 \times 10^{16}$ cm$^{-3}$). These changes align the hole-transport energy levels, accelerate PL quenching, enlarge perovskite grains, and reduce leakage current, producing the reported efficiency and stability gains. The paper frames this passivation as interface engineering that enhances the defect formation energy at the buried interface, which is why the stability improvement accompanies the efficiency improvement.

Load-bearing premise

The load-bearing assumption is that the measured signatures—the S ratio change from 5.29 to 4.56, the 0.20 eV Pb 4f shift, and the trap-filled-limit voltage drop from 0.787 to 0.701 V—are caused specifically by gefitinib's PSS removal and defect passivation, not by run-to-run processing variation or measurement artifacts.

Editorial extensions

If this is right

  • Inverted perovskite cells using gefitinib-treated PEDOT:PSS should reproducibly gain about 30 mV in open-circuit voltage and about 2.6 percentage points in power conversion efficiency, with better humidity tolerance for unencapsulated devices.
  • The method provides an alternative to doping PEDOT:PSS for energy-level alignment, since it modifies the surface rather than the bulk and removes the acidic, water-absorbing PSS chains that hurt stability.
  • Because the same molecule also works at the SnO2/perovskite interface, the functional-group passivation effect appears transferable to other charge-transport layers and device architectures.
  • The reduced PSS ratio and improved transmittance below 630 nm should allow more photons to reach the perovskite, supporting the observed photocurrent increase.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • If the mechanism is general, other small molecules carrying electron-rich halogen or amine groups could be screened computationally for stronger perovskite binding and higher defect formation energy, extending the approach beyond gefitinib itself.
  • The stability gain may come partly from removing acidic, hygroscopic PSS rather than from perovskite passivation alone; a control experiment using a PSS-free hole transporter would separate these two contributions.
  • The reported trap-density reduction assumes a fixed permittivity and film thickness in the SCLC formula; repeating the measurement with multiple perovskite thicknesses and full error statistics would test whether the $1.33 \times 10^{16}$ to $1.18 \times 10^{16}$ cm$^{-3}$ change is robust.
  • Applying gefitinib to flexible or tin-lead inverted cells, where PEDOT:PSS acidity is especially damaging, could be a direct follow-up with potentially larger stability dividends.
Share X Bluesky LinkedIn Reddit HN

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

5 major / 5 minor

Summary. The manuscript reports that a gefitinib (Gftn) surface treatment of PEDOT:PSS removes free PSS chains, lowers the PSS/PEDOT ratio (5.29 to 4.56), increases conductivity, shifts the work function from -4.88 to -5.08 eV, and passivates perovskite interface defects through Cl, F, and NH groups. In inverted (p-i-n) devices, the champion PCE increases from 17.01% to 19.63%, with Voc rising from 1.077 to 1.110 V; a similar treatment at the SnO2/perovskite interface raises the n-i-p PCE from 22.46% to 23.89%. Unencapsulated devices retain 52.31% vs. 11.42% of initial PCE after about 900 hours at 35±5% RH. The mechanistic claims are supported by XPS, UPS, PL, SEM, XRD, SCLC, EQE, and J-V measurements, but several load-bearing data sets and controls are missing from the manuscript as submitted.

Significance. If the central mechanism is established, the work is significant: it proposes a simple molecular interlayer that simultaneously removes insulating PSS, improves energy-level alignment, passivates interfacial defects, and substantially improves both efficiency and stability, with apparent transferability from p-i-n to n-i-p architectures. The paper has concrete strengths: direct device measurements, EQE-integrated Jsc consistent with the J-V Jsc, a long-term stability comparison, and a plausible electrostatic-potential rationale for defect passivation. However, the significance is currently capped by missing statistical data, an absent supplementary file, and the lack of a solvent-only control for the key PSS-removal mechanism.

major comments (5)
  1. [Title and Abstract] The title claims that the treatment 'Enhances the Defect Formation Energy,' but no defect formation energy is computed or defined anywhere in the manuscript. The paper reports a trap density N_t extracted from SCLC using the formula N_t = 2ε0εV_TFL/(eL^2); a trap density is not a defect formation energy. The title (and any related wording in the abstract/conclusion) should be corrected to refer to the quantity actually measured, e.g., reduced trap density or increased defect formation energy if it is explicitly calculated.
  2. [§II, Figs. 2b and 2e] The central mechanistic claim that gefitinib specifically removes free PSS chains from the PEDOT:PSS surface is not established because no solvent-only control is reported. The XPS S 2p ratio change (5.29 to 4.56) and the reduced PSS-related optical absorption (Fig. 2e) could equally arise from washing away loosely bound PSS, from residual solvent acting as a secondary dopant, or from sample-to-sample variation. A control treated with the same solvent and identical rinse/spin protocol but without gefitinib is needed to attribute the conductivity gain, work-function shift, and subsequent device improvements to the gefitinib chemistry.
  3. [§II, Fig. 4a and Table S2] The champion J-V parameters (Voc = 1.110 V, Jsc = 22.39 mA cm^-2, FF = 78.96%, PCE = 19.63%) are presented without error bars or statistical significance in the main text. The claim of a statistically meaningful improvement rests entirely on 'Table S2' (30-device statistics), which is referenced but not supplied in the submission. The supplementary material must be provided, or the statistics must be reported in the main text, before the efficiency improvement can be evaluated.
  4. [§II, SCLC defect-density calculation] The quantitative defect-density claim (N_t decreasing from 1.33×10^16 to 1.18×10^16 cm^-3) depends on the assumed relative permittivity and on L = 450 nm, but no value for ε is given, no error bars are provided, and the raw SCLC curves are only in Figure S7, which is not supplied. Since this SCLC result is the only direct quantitative evidence for defect passivation, the manuscript should state the assumed permittivity, report the uncertainty in V_TFL and L, and include the raw data or clearly identify the missing supplementary figure.
  5. [§II, Fig. 4f] The stability conclusion (52.31% vs. 11.42% retention after ~900 h) is based on what appears to be a single trace per condition, with no number of devices, no error bars, and no replicate data. Given that the abstract and conclusions emphasize 'significantly enhancing the stability,' replicate stability data or at least a statement of the number of devices and measurement uncertainty should be provided.
minor comments (5)
  1. [§II (text near Fig. 3)] The sentence 'The grain size distribution within the range of th e statistical ranget was displayed in Figure S5' contains a typo and a cut-off phrase; it should read 'the statistical range' or similar.
  2. [Throughout] The abbreviation 'Spiro-OMETAD' is used inconsistently; the standard abbreviation is 'Spiro-OMeTAD' (2,2',7,7'-tetrakis(N,N-di-p-methoxyphenylamine)-9,9'-spirobifluorene).
  3. [Author Contributions] The Author Contributions section lists Nian Liu, Jilong Sun, Luyang Liu, and Ping Li, but these names do not appear in the author list of the manuscript; conversely, authorship is not clearly reconciled. The contributions section should be aligned with the actual author list.
  4. [Fig. 2e] The text states that both absorption peaks originate from PSS chains but does not assign the two peaks or explain why no PEDOT-related absorption is observed; a brief assignment would improve clarity.
  5. [§II, Fig. 4c] The hysteresis coefficient is reported as decreasing from 0.03 to 0.02, but the scan-direction J-V curves are only described qualitatively; including the explicit forward/reverse parameters in the text or a table would make the comparison reproducible.

Circularity Check

0 steps flagged · score 0.0 of 10

No significant circularity: the central claims rest on direct measurements, and the few self-citations are contextual rather than load-bearing.

full rationale

The paper's central claims are supported by direct experimental measurements reported in this manuscript: the XPS S 2p ratio decreases from 5.29 to 4.56 (Figure 2b), the PSS-related absorption peak decreases (Figure 2e), conductivity increases (Figure 2c), UPS-derived work function shifts from -4.88 to -5.08 eV, the Pb 4f peaks shift by 0.20 eV (Figure S4), SCLC VTFL decreases from 0.787 to 0.701 V, and champion device Voc/PCE improve from 1.077 V/17.01% to 1.110 V/19.63%. The defect density is computed from the measured VTFL using the standard formula Nt = (2*epsilon0*epsilon*VTFL)/(e*L^2) with stated assumptions; no fitted parameter is renamed as a prediction. The self-citations (refs 23 and 28) are used for background interpretation: ref 23 supports the general statement that reducing the PSS-to-PEDOT ratio is beneficial for conductivity, and ref 28 is cited alongside refs 29-30 for interpreting Pb 4f binding-energy shifts as evidence of interaction. In both cases the relevant quantities (conductivity, Pb 4f shift) are measured in this paper, so the citations are not load-bearing and do not make the derivation circular. The title's phrase 'defect formation energy' is never computed, and the mechanism lacks a solvent-only control, but these are correctness or completeness concerns, not circularity. No equation in the paper reduces a predicted quantity to an input by construction, and no central claim is forced by a self-citation chain. The appropriate finding is no significant circularity.

Assumptions & free parameters 1 free parameters · 6 assumptions · 0 invented entities

No numbers are fitted in a derivation; the paper is experimental. The main hidden inputs are the assumed validity of XPS, UPS, and SCLC quantification, and the attribution of device gains to gefitinib. The concentration of gefitinib is an experimental choice, not a physical constant.

free parameters (1)
  • Gefitinib concentration (chosen as '3-Gftn') = not stated in main text
    The optimum is selected from a 30-device concentration series referenced as Table S2, which is not included in the supplied text. The reported efficiency gain depends on this hand-selected experimental condition.
assumptions (6)
  • domain assumption The SCLC trap-filled-limit formula Nt = 2*epsilon0*epsilon*VTFL/(e*L^2) yields a valid interface/bulk defect density.
    Used to quantify defect passivation; requires assumed relative permittivity and L = 450 nm, neither with uncertainty estimates in the supplied text.
  • domain assumption XPS S 2p peak areas accurately quantify the PSS/PEDOT ratio change from 5.29 to 4.56.
    This ratio is the main evidence for removal of free PSS chains; peak fitting, calibration, and error bars are not shown.
  • domain assumption F, Cl, and NH groups in gefitinib passivate uncoordinated Pb defects in the perovskite.
    Inferred from the ESP map and a 0.20 eV Pb 4f XPS shift; no direct binding-energy calculation or control experiments isolating each group are provided.
  • domain assumption UPS-derived energy levels (work function -5.08 eV and VBM -5.26 eV for 3-Gftn) reflect the operative interface band alignment.
    Improved hole extraction is attributed to this 0.17 eV VBM shift; UPS cutoff values are reported without measurement uncertainty.
  • domain assumption All device performance differences between Control and 3-Gftn are caused by the gefitinib treatment, not by processing drift.
    Only champion J-V curves are shown in the main text; 30-device statistics are relegated to Table S2, which is not included in the supplied text.
  • domain assumption Unencapsulated stability testing at 35 +/- 5% RH for about 900 hours is representative of operational stability.
    No encapsulation, temperature cycling, maximum-power-point tracking, or reproducibility across multiple batches is reported.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Gefitinib-Induced Interface Engineering Enhances the Defect Formation Energy for Highly Efficient and Stable Perovskite Solar Cells." pith.science (2026). https://pith.science/paper/ZWCSJP4Y

@misc{pith2026250603611,
  author       = {Pith},
  title        = {Pith review of: Gefitinib-Induced Interface Engineering Enhances the Defect Formation Energy for Highly Efficient and Stable Perovskite Solar Cells},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/ZWCSJP4Y}},
  note         = {Machine review of arXiv:2506.03611}
}
read the original abstract

Poly(3,4-ethylenedioxythiophene):polystyrenesulfonate (PEDOT:PSS) has been widely used as a hole transport layer in perovskite solar cells (PSCs). However, the high interface defect density and energy level mismatch between PEDOT:PSS and perovskite can lead to significant open-circuit voltage loss. Additionally, the free PSS chains on the surface of PEDOT:PSS can absorb water molecules, promoting the degradation of perovskite at the PEDOT:PSS/perovskite interface. Here, gefitinib is used to modify the surface of PEDOT:PSS, removing a portion of the free PSS chains from the surface, reducing the PSS/PEDOT ratio, and enhancing the conductivity of PEDOT:PSS. Gefitinib has altered the energy level structure of PEDOT:PSS, facilitating hole transport at the interface. The Cl, F, and NH groups in gefitinib also passivated defects in the perovskite, reducing the defect density at the interface and significantly enhancing the stability of PSCs. This modification increased the open-circuit voltage from 1.077 to 1.110 V and the power conversion efficiency (PCE) from 17.01% to 19.63%. When gefitinib was used to modify the interface between SnO2 and perovskite, the PCE of PSCs (ITO/SnO2/perovskite/Spiro-OMETAD/Au) increased from 22.46% to 23.89%. This approach provides new perspectives and strategies for improving the efficiency and stability of PSCs.

Discussion (0). Sign in to comment.

Reference graph

Works this paper leans on

8 extracted references · 8 canonical work pages

  1. [1]

    1 X. Wu, J. Bi, G. Cui, J. Jiang, H. Tang, N. Liu, G. Xia, J. Sun, N. Lu, P. Li, C. Zhao, Z. Zuo, and M. Gu, ACS Photonics 12(2), 997 (2025). 2 G. Hu, J. Guo, J. Jiang, L. Wang, J. Zhang, H. Chen, G. Lou, W. Wei, and L. Shen, Light. Sci. Appl. 14(1), 61 (2025). 3 H. Wang, A. Treglia, M. D. Albaqami, F. Gao, and A. Petrozza, ACS Energy Lett. 9(6), 2500 (20...

    work page 2025

  2. [2]

    Li, Energy Environ. Sci. 17(21), 8337 (2024). 10 M. Zeng, Z. Yan, X. Ye, Y . Lou, T. Sheng, X. Jiang, Y . Mao, A. Huang, X. Yang, Z

    work page 2024

  3. [3]

    Wang, Y . Sun, Y . Bai, H.-M. Cheng, and G. Xing, ACS Energy Lett. 10, 1357 (2025). 11 T. H. Kim, B. W. Kim, and S. H. Im, Adv. Electron. Mater. 2400626 (2024). 12 W.-M. Gu, K.-J. Jiang, X. Jiao, L. Wu, C.-Y . Gao, X.-H. Fan, L.-M. Yang, Q. Wang, and Y . Song, Chem. Eng. J. 485, 149512 (2024). 13 M. Chen, G. Kapil , L. Wang, S. Razey Sahamir, A. K. Baranw...

    work page 2025

  4. [4]

    Zhang, M

    Sanehira, Z. Zhang, M. Akmal Kamarudin, Q. Shen, and S. Hayase, Chem. Eng. J. 436, 135196 (2022). 14 K. Cao, H. Ning, N. Xu, W. Zuo, Y . Zhang, M. Yang, J. Xia, L. Liu, and S. Chen, J. Mater. Chem. A 12(28), 17444 (2024). 15 R. Zhang, H. Ling, X. Lu, and J. Xia, Sol. Energy 186, 398 (2019). 16 Y . Yang, Y . Li, Y . Yao, X. Zhao, S. Wu, L. Qin, X. Yang, P....

    work page 2022

  5. [5]

    Zhou, Nat. Commun. 15(1), 4136 (2024). 21 J. Song, T. Kong, Z. Zhao, Y . Zhang, Y . Liu, and D. Bi, Adv. Funct. Mater. 35(3), 2411746 (2024). 22 J. Zhang, W. Li, X. Lv, Y . Ji, W. Huang, T. Bu, Z. Ren, C. Yao, F. Huang, Y . B. Cheng, and J. Tong, Sol. RRL 8(11), 2400184 (2024). 23 X. Wu, X. Tang, X. Dong, Z. Jiang, N. Liu, J. Bao, G. Cui, C. Zhao, L. Kong, and M

    work page 2024

  6. [6]

    Status Solidi A

    Gu, Phys. Status Solidi A. 219(18), 2200163 (2022). 24 W. Xu, Y . Zhang, Y . Huang, Y . Tao, J. Wang, W. Liu, D. Wang, Z. Zhang, J. Xiong, and J. Zhang, Small 21(7), 2407063 (2025). 25 X. Liu, Y . Guo, Y . Cheng, S. Lu, R. Li, and J. Chen, Chem. Commun. 59(90), 13394 (2023). 26 X. Jiang, G. Yang, B. Zhang, L. Wang, Y . Yin, F. Zhang, S. Yu, S. Liu, H. Bu,...

    work page 2022

  7. [7]

    Yang, and Y

    Liu, L. Yang, and Y . Yan, Chem. Eng. J. 490, 151778 (2024). 30 X. Zhuang, D. Zhou, S. Liu, R. Sun, Z. Shi, L. Liu, T. Wang, B. Liu, D. Liu, and H

    work page 2024

  8. [8]

    Energy Mater

    Song, Adv. Energy Mater. 12(25), 2200614 (2022)

    work page 2022

Pith tools

Reviewed August 7, 2026 · model on record in the stance chip above.